215 related articles for article (PubMed ID: 35409162)
1. The Activity of Ten Natural Extracts Combined in a Unique Blend to Maintain Cholesterol Homeostasis-In Vitro Model.
Ruga S; Galla R; Penna C; Molinari C; Uberti F
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409162
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
3. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
4. Keep recycling going: New approaches to reduce LDL-C.
Klein-Szanto AJP; Bassi DE
Biochem Pharmacol; 2019 Jun; 164():336-341. PubMed ID: 30953636
[TBL] [Abstract][Full Text] [Related]
5. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
6. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
7. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
8. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
9. PCSK9 in cholesterol metabolism: from bench to bedside.
Reiss AB; Shah N; Muhieddine D; Zhen J; Yudkevich J; Kasselman LJ; DeLeon J
Clin Sci (Lond); 2018 Jun; 132(11):1135-1153. PubMed ID: 29895529
[TBL] [Abstract][Full Text] [Related]
10. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.
Alla VM; Agrawal V; DeNazareth A; Mohiuddin S; Ravilla S; Rendell M
Drugs; 2013 Jul; 73(10):1025-54. PubMed ID: 23754124
[TBL] [Abstract][Full Text] [Related]
11. Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes.
Ahangari N; Ghayour Mobarhan M; Sahebkar A; Pasdar A
Ann Med; 2018 Jun; 50(4):303-311. PubMed ID: 29578362
[TBL] [Abstract][Full Text] [Related]
12. [Atorvastatin (Lipitor): a review of its pharmacological and clinical profile].
Funatsu T; Kakuta H; Tanaka H; Arai Y; Suzuki K; Miyata K
Nihon Yakurigaku Zasshi; 2001 Jan; 117(1):65-76. PubMed ID: 11233299
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
Okere AN; Serra C
Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
[TBL] [Abstract][Full Text] [Related]
14. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
[TBL] [Abstract][Full Text] [Related]
15. Comparing HMG-CoA reductase inhibitors.
Jones PH
Clin Cardiol; 2003 Jan; 26(1 Suppl 1):I15-20. PubMed ID: 12539818
[TBL] [Abstract][Full Text] [Related]
16. Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea.
Jeong YJ; Kim H; Baik SJ; Kim TM; Yang SJ; Lee SH; Cho JH; Lee H; Yim HW; Choi IY; Yoon KH; Kim HS
J Clin Pharm Ther; 2017 Jun; 42(3):292-300. PubMed ID: 28251662
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature.
Yu M; Liang C; Kong Q; Wang Y; Li M
Lipids Health Dis; 2020 Jan; 19(1):1. PubMed ID: 31900179
[TBL] [Abstract][Full Text] [Related]
18. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
Geiss HC; Otto C; Parhofer KG
Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On Study.
Bissonnette S; Habib R; Sampalis F; Boukas S; Sampalis JS;
Can J Cardiol; 2006 Oct; 22(12):1035-44. PubMed ID: 17036098
[TBL] [Abstract][Full Text] [Related]
20. Human cholesterol metabolism and therapeutic molecules.
Charlton-Menys V; Durrington PN
Exp Physiol; 2008 Jan; 93(1):27-42. PubMed ID: 18165431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
